Theralase Research Accepted at International Conference
22 4월 2014 - 7:59PM
Access Wire
TORONTO, ONTARIO / ACCESSWIRE / April 22, 2014 / Theralase
Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that
its Photo Dynamic Compound (PDC) technology, proven effective in
the destruction of bacteria and cancer, has been peer reviewed and
approved for presentation at the renowned International Conference
on Laser Applications in Life Sciences to take place in Ulm,
Germany in June 2014.
Theralase's ability to destroy two types of bacteria
(Staphylococcus aureus and Methicillin Resistant Staphylococcus
aureus (MRSA)) up to 99.99999% with a new class of PDCs has caught
the attention of the global scientific and medical community after
recent publication in the journal Photodiagnosis and Photodynamic
Therapy.
The latest Theralase research is considered pivotal by the
international community because the PDCs were able to destroy two
types of bacteria in both normal and low oxygenated tissue in
nanomolar concentrations (micrograms of the PDCs were lethal to
bacteria when light activated) and were proven especially effective
in low oxygen environments, where certain types of bacteria and
cancer thrive.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated
that, "Theralase's PDC technology addresses the challenge of
bacteria that develop an immunity to destruction due to an acquired
resistance to treatment, such as antibiotic drugs. The latest
research confirms that the Theralase PDCs are a reliable
alternative to antibiotics and have none of the acquired resistance
limitations. This new approach provides a novel and effective
treatment to destroying bacteria by improving selectivity, reducing
treatment time and improving safety for clinical applications,
which is critical for a broad international acceptance of the
technology. Moreover, the fact that the Theralase PDCs are
effective in low oxygen and have a higher stability than FDA
approved PDCs may have a tremendous impact in limiting the further
spread of antibiotic-resistant strains of bacteria and
simultaneously provide superior health care worldwide."
Roger Dumoulin-White, President and CEO of Theralase stated
that, "I am delighted that our research in PDCs has attracted the
international attention of the scientific and medical community. By
being extremely effective in microgram concentrations, Theralase
now has the opportunity for early partnership with large
pharmaceutical organizations interested in alternatives to
antibiotics for bacteria destruction. This is a billion dollar
market in need of technology that is able to eliminate the
bacterial load quickly and effectively, while minimizing risk to
the patient."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets
patented, superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint conditions.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when light
activated.
Additional information is available at www.theralase.com and
www.sedar.com .
This press release contains forward-looking statements, which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024